Oncology In 21st Century Cures: Heading Toward A Two-FDA Solution?
Executive Summary
The 21st Century Cures Act regulatory reform provisions amount to a lot of little things: tweaks to encourage ongoing activities rather than bold departures at a time when the overall regulatory climate is good for innovators. But the law could also be the start of something bigger – a more formal division within the US FDA between oncology and everything else.
You may also be interested in...
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
CDER's OHOP, as well as relevant CBER and CDRH staff, should be folded into OCE, which should have final sign-off on all oncology products, ASCO and Friends of Cancer Research say.
US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb
Analyst poll of 53 drug companies indicates broad support for Scott Gottlieb compared to three other known candidates for FDA Commissioner.
CDER’s 50 Open Leadership Posts Could Be Bigger Hiring Challenges After Trump Freeze
President Trump’s hiring freeze on civilian employees will exacerbate the Center for Drugs Evaluation & Research’s existing difficulties in recruiting and retaining qualified individuals. CDER is currently 591 positions under the hiring ceiling, include 50 open positions within CDER management.